nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—osteoporosis	0.353	1	CbGaD
Thalidomide—PTGS2—Risedronate—osteoporosis	0.106	0.325	CbGbCtD
Thalidomide—CYP1A1—Cholecalciferol—osteoporosis	0.0351	0.107	CbGbCtD
Thalidomide—CYP1A2—Estropipate—osteoporosis	0.0304	0.0928	CbGbCtD
Thalidomide—CYP1A1—Estradiol—osteoporosis	0.0283	0.0863	CbGbCtD
Thalidomide—CYP2C9—Estropipate—osteoporosis	0.0274	0.0836	CbGbCtD
Thalidomide—CYP2C19—Cholecalciferol—osteoporosis	0.017	0.0518	CbGbCtD
Thalidomide—CYP3A5—Estradiol—osteoporosis	0.017	0.0518	CbGbCtD
Thalidomide—CYP1A2—Conjugated Estrogens—osteoporosis	0.0144	0.0439	CbGbCtD
Thalidomide—CYP2C9—Cholecalciferol—osteoporosis	0.0141	0.0431	CbGbCtD
Thalidomide—CYP2C19—Estradiol—osteoporosis	0.0137	0.0418	CbGbCtD
Thalidomide—CYP1A2—Estradiol—osteoporosis	0.0126	0.0385	CbGbCtD
Thalidomide—CYP2C9—Estradiol—osteoporosis	0.0114	0.0347	CbGbCtD
Thalidomide—Lenalidomide—TNFSF11—osteoporosis	0.00419	0.64	CrCbGaD
Thalidomide—FGFR2—skull—osteoporosis	0.00286	0.401	CbGeAlD
Thalidomide—FGFR2—Estradiol—Estropipate—osteoporosis	0.00134	0.418	CbGdCrCtD
Thalidomide—Menadione—BGLAP—osteoporosis	0.0011	0.168	CrCbGaD
Thalidomide—PTGS2—periosteum—osteoporosis	0.00106	0.148	CbGeAlD
Thalidomide—FGFR2—Estradiol—Conjugated Estrogens—osteoporosis	0.00101	0.316	CbGdCrCtD
Thalidomide—FGFR2—Estradiol—Ethinyl Estradiol—osteoporosis	0.000851	0.266	CbGdCrCtD
Thalidomide—Pomalidomide—TNF—osteoporosis	0.000796	0.122	CrCbGaD
Thalidomide—NFKB1—uterus—osteoporosis	0.000634	0.0888	CbGeAlD
Thalidomide—NFKB1—bone marrow—osteoporosis	0.000538	0.0753	CbGeAlD
Thalidomide—CRBN—uterus—osteoporosis	0.000531	0.0744	CbGeAlD
Thalidomide—FGFR2—uterus—osteoporosis	0.000476	0.0667	CbGeAlD
Thalidomide—Menadione—MTHFR—osteoporosis	0.000463	0.0708	CrCbGaD
Thalidomide—CRBN—bone marrow—osteoporosis	0.000451	0.0632	CbGeAlD
Thalidomide—CYP1A1—uterus—osteoporosis	0.000172	0.0241	CbGeAlD
Thalidomide—PTGS1—uterus—osteoporosis	0.000151	0.0212	CbGeAlD
Thalidomide—PTGS2—uterus—osteoporosis	0.000145	0.0203	CbGeAlD
Thalidomide—PTGS2—bone marrow—osteoporosis	0.000123	0.0172	CbGeAlD
Thalidomide—Hypotension—Pamidronate—osteoporosis	7.78e-05	0.000396	CcSEcCtD
Thalidomide—Convulsion—Conjugated Estrogens—osteoporosis	7.77e-05	0.000396	CcSEcCtD
Thalidomide—Dry mouth—Zoledronate—osteoporosis	7.76e-05	0.000395	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	7.75e-05	0.000395	CcSEcCtD
Thalidomide—Fatigue—Ethinyl Estradiol—osteoporosis	7.74e-05	0.000394	CcSEcCtD
Thalidomide—Pruritus—Alendronate—osteoporosis	7.72e-05	0.000393	CcSEcCtD
Thalidomide—Dyspepsia—Risedronate—osteoporosis	7.71e-05	0.000393	CcSEcCtD
Thalidomide—Eye disorder—Estradiol—osteoporosis	7.71e-05	0.000393	CcSEcCtD
Thalidomide—Tinnitus—Estradiol—osteoporosis	7.69e-05	0.000392	CcSEcCtD
Thalidomide—Constipation—Ethinyl Estradiol—osteoporosis	7.68e-05	0.000391	CcSEcCtD
Thalidomide—Confusional state—Zoledronate—osteoporosis	7.67e-05	0.00039	CcSEcCtD
Thalidomide—Hypersensitivity—Calcitriol—osteoporosis	7.66e-05	0.00039	CcSEcCtD
Thalidomide—Cardiac disorder—Estradiol—osteoporosis	7.65e-05	0.00039	CcSEcCtD
Thalidomide—Chest pain—Conjugated Estrogens—osteoporosis	7.64e-05	0.000389	CcSEcCtD
Thalidomide—Arthralgia—Conjugated Estrogens—osteoporosis	7.64e-05	0.000389	CcSEcCtD
Thalidomide—Myalgia—Conjugated Estrogens—osteoporosis	7.64e-05	0.000389	CcSEcCtD
Thalidomide—Asthenia—Ibandronate—osteoporosis	7.62e-05	0.000388	CcSEcCtD
Thalidomide—Anxiety—Conjugated Estrogens—osteoporosis	7.61e-05	0.000388	CcSEcCtD
Thalidomide—Nausea—Etidronic acid—osteoporosis	7.61e-05	0.000387	CcSEcCtD
Thalidomide—Oedema—Zoledronate—osteoporosis	7.6e-05	0.000387	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	7.58e-05	0.000386	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Pamidronate—osteoporosis	7.58e-05	0.000386	CcSEcCtD
Thalidomide—Diarrhoea—Estropipate—osteoporosis	7.58e-05	0.000386	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Risedronate—osteoporosis	7.56e-05	0.000385	CcSEcCtD
Thalidomide—Infection—Zoledronate—osteoporosis	7.55e-05	0.000385	CcSEcCtD
Thalidomide—Fatigue—Risedronate—osteoporosis	7.55e-05	0.000384	CcSEcCtD
Thalidomide—Insomnia—Pamidronate—osteoporosis	7.53e-05	0.000383	CcSEcCtD
Thalidomide—Pruritus—Ibandronate—osteoporosis	7.52e-05	0.000383	CcSEcCtD
Thalidomide—Pain—Risedronate—osteoporosis	7.49e-05	0.000381	CcSEcCtD
Thalidomide—Constipation—Risedronate—osteoporosis	7.49e-05	0.000381	CcSEcCtD
Thalidomide—Angiopathy—Estradiol—osteoporosis	7.48e-05	0.000381	CcSEcCtD
Thalidomide—Shock—Zoledronate—osteoporosis	7.48e-05	0.000381	CcSEcCtD
Thalidomide—Paraesthesia—Pamidronate—osteoporosis	7.47e-05	0.000381	CcSEcCtD
Thalidomide—Diarrhoea—Alendronate—osteoporosis	7.47e-05	0.00038	CcSEcCtD
Thalidomide—Asthenia—Calcitriol—osteoporosis	7.46e-05	0.00038	CcSEcCtD
Thalidomide—Nervous system disorder—Zoledronate—osteoporosis	7.46e-05	0.00038	CcSEcCtD
Thalidomide—Immune system disorder—Estradiol—osteoporosis	7.45e-05	0.000379	CcSEcCtD
Thalidomide—Thrombocytopenia—Zoledronate—osteoporosis	7.44e-05	0.000379	CcSEcCtD
Thalidomide—Mediastinal disorder—Estradiol—osteoporosis	7.43e-05	0.000379	CcSEcCtD
Thalidomide—Dyspnoea—Pamidronate—osteoporosis	7.42e-05	0.000378	CcSEcCtD
Thalidomide—Tachycardia—Zoledronate—osteoporosis	7.42e-05	0.000378	CcSEcCtD
Thalidomide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	7.4e-05	0.000377	CcSEcCtD
Thalidomide—Chills—Estradiol—osteoporosis	7.4e-05	0.000377	CcSEcCtD
Thalidomide—Somnolence—Pamidronate—osteoporosis	7.4e-05	0.000377	CcSEcCtD
Thalidomide—Skin disorder—Zoledronate—osteoporosis	7.39e-05	0.000376	CcSEcCtD
Thalidomide—Pruritus—Calcitriol—osteoporosis	7.36e-05	0.000375	CcSEcCtD
Thalidomide—Hyperhidrosis—Zoledronate—osteoporosis	7.35e-05	0.000374	CcSEcCtD
Thalidomide—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	7.34e-05	0.000374	CcSEcCtD
Thalidomide—Diarrhoea—Raloxifene—osteoporosis	7.34e-05	0.000374	CcSEcCtD
Thalidomide—Dyspepsia—Pamidronate—osteoporosis	7.33e-05	0.000373	CcSEcCtD
Thalidomide—Dizziness—Estropipate—osteoporosis	7.33e-05	0.000373	CcSEcCtD
Thalidomide—Oedema—Conjugated Estrogens—osteoporosis	7.32e-05	0.000373	CcSEcCtD
Thalidomide—Alopecia—Estradiol—osteoporosis	7.29e-05	0.000371	CcSEcCtD
Thalidomide—Infection—Conjugated Estrogens—osteoporosis	7.27e-05	0.00037	CcSEcCtD
Thalidomide—Diarrhoea—Ibandronate—osteoporosis	7.27e-05	0.00037	CcSEcCtD
Thalidomide—Anorexia—Zoledronate—osteoporosis	7.25e-05	0.000369	CcSEcCtD
Thalidomide—Decreased appetite—Pamidronate—osteoporosis	7.24e-05	0.000369	CcSEcCtD
Thalidomide—Mental disorder—Estradiol—osteoporosis	7.23e-05	0.000368	CcSEcCtD
Thalidomide—Dizziness—Alendronate—osteoporosis	7.22e-05	0.000368	CcSEcCtD
Thalidomide—Shock—Conjugated Estrogens—osteoporosis	7.2e-05	0.000367	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Pamidronate—osteoporosis	7.19e-05	0.000366	CcSEcCtD
Thalidomide—Nervous system disorder—Conjugated Estrogens—osteoporosis	7.18e-05	0.000366	CcSEcCtD
Thalidomide—Malnutrition—Estradiol—osteoporosis	7.18e-05	0.000366	CcSEcCtD
Thalidomide—Fatigue—Pamidronate—osteoporosis	7.18e-05	0.000366	CcSEcCtD
Thalidomide—Gastrointestinal pain—Risedronate—osteoporosis	7.16e-05	0.000365	CcSEcCtD
Thalidomide—Tachycardia—Conjugated Estrogens—osteoporosis	7.15e-05	0.000364	CcSEcCtD
Thalidomide—Urticaria—Ethinyl Estradiol—osteoporosis	7.13e-05	0.000363	CcSEcCtD
Thalidomide—Pain—Pamidronate—osteoporosis	7.12e-05	0.000363	CcSEcCtD
Thalidomide—Constipation—Pamidronate—osteoporosis	7.12e-05	0.000363	CcSEcCtD
Thalidomide—Diarrhoea—Calcitriol—osteoporosis	7.12e-05	0.000362	CcSEcCtD
Thalidomide—Skin disorder—Conjugated Estrogens—osteoporosis	7.11e-05	0.000362	CcSEcCtD
Thalidomide—Hypotension—Zoledronate—osteoporosis	7.1e-05	0.000362	CcSEcCtD
Thalidomide—Abdominal pain—Ethinyl Estradiol—osteoporosis	7.1e-05	0.000362	CcSEcCtD
Thalidomide—Body temperature increased—Ethinyl Estradiol—osteoporosis	7.1e-05	0.000362	CcSEcCtD
Thalidomide—Dizziness—Raloxifene—osteoporosis	7.1e-05	0.000361	CcSEcCtD
Thalidomide—Hyperhidrosis—Conjugated Estrogens—osteoporosis	7.08e-05	0.00036	CcSEcCtD
Thalidomide—Flatulence—Estradiol—osteoporosis	7.07e-05	0.00036	CcSEcCtD
Thalidomide—Tension—Estradiol—osteoporosis	7.04e-05	0.000359	CcSEcCtD
Thalidomide—Vomiting—Estropipate—osteoporosis	7.04e-05	0.000359	CcSEcCtD
Thalidomide—Dysgeusia—Estradiol—osteoporosis	7.03e-05	0.000358	CcSEcCtD
Thalidomide—Dizziness—Ibandronate—osteoporosis	7.03e-05	0.000358	CcSEcCtD
Thalidomide—Rash—Estropipate—osteoporosis	6.99e-05	0.000356	CcSEcCtD
Thalidomide—Dermatitis—Estropipate—osteoporosis	6.98e-05	0.000355	CcSEcCtD
Thalidomide—Anorexia—Conjugated Estrogens—osteoporosis	6.98e-05	0.000355	CcSEcCtD
Thalidomide—Nervousness—Estradiol—osteoporosis	6.97e-05	0.000355	CcSEcCtD
Thalidomide—Urticaria—Risedronate—osteoporosis	6.96e-05	0.000354	CcSEcCtD
Thalidomide—Back pain—Estradiol—osteoporosis	6.94e-05	0.000354	CcSEcCtD
Thalidomide—Headache—Estropipate—osteoporosis	6.94e-05	0.000354	CcSEcCtD
Thalidomide—Vomiting—Alendronate—osteoporosis	6.94e-05	0.000353	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Zoledronate—osteoporosis	6.93e-05	0.000353	CcSEcCtD
Thalidomide—Body temperature increased—Risedronate—osteoporosis	6.92e-05	0.000353	CcSEcCtD
Thalidomide—Abdominal pain—Risedronate—osteoporosis	6.92e-05	0.000353	CcSEcCtD
Thalidomide—Muscle spasms—Estradiol—osteoporosis	6.9e-05	0.000352	CcSEcCtD
Thalidomide—Rash—Alendronate—osteoporosis	6.88e-05	0.00035	CcSEcCtD
Thalidomide—Insomnia—Zoledronate—osteoporosis	6.88e-05	0.00035	CcSEcCtD
Thalidomide—Dermatitis—Alendronate—osteoporosis	6.87e-05	0.00035	CcSEcCtD
Thalidomide—Feeling abnormal—Pamidronate—osteoporosis	6.86e-05	0.000349	CcSEcCtD
Thalidomide—Hypotension—Conjugated Estrogens—osteoporosis	6.84e-05	0.000348	CcSEcCtD
Thalidomide—Headache—Alendronate—osteoporosis	6.84e-05	0.000348	CcSEcCtD
Thalidomide—Paraesthesia—Zoledronate—osteoporosis	6.83e-05	0.000348	CcSEcCtD
Thalidomide—Vomiting—Raloxifene—osteoporosis	6.82e-05	0.000348	CcSEcCtD
Thalidomide—Gastrointestinal pain—Pamidronate—osteoporosis	6.81e-05	0.000347	CcSEcCtD
Thalidomide—Dyspnoea—Zoledronate—osteoporosis	6.78e-05	0.000345	CcSEcCtD
Thalidomide—Rash—Raloxifene—osteoporosis	6.77e-05	0.000345	CcSEcCtD
Thalidomide—Dermatitis—Raloxifene—osteoporosis	6.76e-05	0.000344	CcSEcCtD
Thalidomide—Somnolence—Zoledronate—osteoporosis	6.76e-05	0.000344	CcSEcCtD
Thalidomide—Vomiting—Ibandronate—osteoporosis	6.76e-05	0.000344	CcSEcCtD
Thalidomide—Tremor—Estradiol—osteoporosis	6.73e-05	0.000343	CcSEcCtD
Thalidomide—Headache—Raloxifene—osteoporosis	6.72e-05	0.000342	CcSEcCtD
Thalidomide—Rash—Ibandronate—osteoporosis	6.7e-05	0.000341	CcSEcCtD
Thalidomide—Dermatitis—Ibandronate—osteoporosis	6.69e-05	0.000341	CcSEcCtD
Thalidomide—Dyspepsia—Zoledronate—osteoporosis	6.69e-05	0.000341	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	6.67e-05	0.00034	CcSEcCtD
Thalidomide—Ill-defined disorder—Estradiol—osteoporosis	6.66e-05	0.000339	CcSEcCtD
Thalidomide—Headache—Ibandronate—osteoporosis	6.66e-05	0.000339	CcSEcCtD
Thalidomide—Insomnia—Conjugated Estrogens—osteoporosis	6.62e-05	0.000337	CcSEcCtD
Thalidomide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	6.62e-05	0.000337	CcSEcCtD
Thalidomide—Vomiting—Calcitriol—osteoporosis	6.61e-05	0.000337	CcSEcCtD
Thalidomide—Decreased appetite—Zoledronate—osteoporosis	6.61e-05	0.000337	CcSEcCtD
Thalidomide—Agitation—Estradiol—osteoporosis	6.6e-05	0.000336	CcSEcCtD
Thalidomide—Nausea—Estropipate—osteoporosis	6.58e-05	0.000335	CcSEcCtD
Thalidomide—Abdominal pain—Pamidronate—osteoporosis	6.58e-05	0.000335	CcSEcCtD
Thalidomide—Body temperature increased—Pamidronate—osteoporosis	6.58e-05	0.000335	CcSEcCtD
Thalidomide—Paraesthesia—Conjugated Estrogens—osteoporosis	6.57e-05	0.000335	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Zoledronate—osteoporosis	6.56e-05	0.000334	CcSEcCtD
Thalidomide—Angioedema—Estradiol—osteoporosis	6.56e-05	0.000334	CcSEcCtD
Thalidomide—Rash—Calcitriol—osteoporosis	6.56e-05	0.000334	CcSEcCtD
Thalidomide—Fatigue—Zoledronate—osteoporosis	6.56e-05	0.000334	CcSEcCtD
Thalidomide—Dermatitis—Calcitriol—osteoporosis	6.55e-05	0.000334	CcSEcCtD
Thalidomide—Dyspnoea—Conjugated Estrogens—osteoporosis	6.53e-05	0.000332	CcSEcCtD
Thalidomide—Headache—Calcitriol—osteoporosis	6.52e-05	0.000332	CcSEcCtD
Thalidomide—Somnolence—Conjugated Estrogens—osteoporosis	6.51e-05	0.000331	CcSEcCtD
Thalidomide—Pain—Zoledronate—osteoporosis	6.5e-05	0.000331	CcSEcCtD
Thalidomide—Constipation—Zoledronate—osteoporosis	6.5e-05	0.000331	CcSEcCtD
Thalidomide—Nausea—Alendronate—osteoporosis	6.48e-05	0.00033	CcSEcCtD
Thalidomide—Malaise—Estradiol—osteoporosis	6.47e-05	0.00033	CcSEcCtD
Thalidomide—Hypersensitivity—Risedronate—osteoporosis	6.45e-05	0.000329	CcSEcCtD
Thalidomide—Vertigo—Estradiol—osteoporosis	6.45e-05	0.000329	CcSEcCtD
Thalidomide—Dyspepsia—Conjugated Estrogens—osteoporosis	6.44e-05	0.000328	CcSEcCtD
Thalidomide—Asthenia—Ethinyl Estradiol—osteoporosis	6.44e-05	0.000328	CcSEcCtD
Thalidomide—Syncope—Estradiol—osteoporosis	6.44e-05	0.000328	CcSEcCtD
Thalidomide—Nausea—Raloxifene—osteoporosis	6.37e-05	0.000325	CcSEcCtD
Thalidomide—Decreased appetite—Conjugated Estrogens—osteoporosis	6.36e-05	0.000324	CcSEcCtD
Thalidomide—Pruritus—Ethinyl Estradiol—osteoporosis	6.35e-05	0.000324	CcSEcCtD
Thalidomide—Palpitations—Estradiol—osteoporosis	6.34e-05	0.000323	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	6.32e-05	0.000322	CcSEcCtD
Thalidomide—Fatigue—Conjugated Estrogens—osteoporosis	6.31e-05	0.000321	CcSEcCtD
Thalidomide—Nausea—Ibandronate—osteoporosis	6.31e-05	0.000321	CcSEcCtD
Thalidomide—Loss of consciousness—Estradiol—osteoporosis	6.31e-05	0.000321	CcSEcCtD
Thalidomide—Asthenia—Risedronate—osteoporosis	6.28e-05	0.00032	CcSEcCtD
Thalidomide—Feeling abnormal—Zoledronate—osteoporosis	6.27e-05	0.000319	CcSEcCtD
Thalidomide—Cough—Estradiol—osteoporosis	6.26e-05	0.000319	CcSEcCtD
Thalidomide—Pain—Conjugated Estrogens—osteoporosis	6.26e-05	0.000319	CcSEcCtD
Thalidomide—Constipation—Conjugated Estrogens—osteoporosis	6.26e-05	0.000319	CcSEcCtD
Thalidomide—Gastrointestinal pain—Zoledronate—osteoporosis	6.22e-05	0.000317	CcSEcCtD
Thalidomide—Hypertension—Estradiol—osteoporosis	6.2e-05	0.000316	CcSEcCtD
Thalidomide—Pruritus—Risedronate—osteoporosis	6.19e-05	0.000316	CcSEcCtD
Thalidomide—Nausea—Calcitriol—osteoporosis	6.18e-05	0.000315	CcSEcCtD
Thalidomide—Diarrhoea—Ethinyl Estradiol—osteoporosis	6.14e-05	0.000313	CcSEcCtD
Thalidomide—Hypersensitivity—Pamidronate—osteoporosis	6.13e-05	0.000312	CcSEcCtD
Thalidomide—Arthralgia—Estradiol—osteoporosis	6.11e-05	0.000311	CcSEcCtD
Thalidomide—Chest pain—Estradiol—osteoporosis	6.11e-05	0.000311	CcSEcCtD
Thalidomide—Myalgia—Estradiol—osteoporosis	6.11e-05	0.000311	CcSEcCtD
Thalidomide—Anxiety—Estradiol—osteoporosis	6.09e-05	0.00031	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	6.07e-05	0.000309	CcSEcCtD
Thalidomide—Urticaria—Zoledronate—osteoporosis	6.04e-05	0.000308	CcSEcCtD
Thalidomide—Discomfort—Estradiol—osteoporosis	6.04e-05	0.000308	CcSEcCtD
Thalidomide—Body temperature increased—Zoledronate—osteoporosis	6.01e-05	0.000306	CcSEcCtD
Thalidomide—Abdominal pain—Zoledronate—osteoporosis	6.01e-05	0.000306	CcSEcCtD
Thalidomide—Diarrhoea—Risedronate—osteoporosis	5.99e-05	0.000305	CcSEcCtD
Thalidomide—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	5.99e-05	0.000305	CcSEcCtD
Thalidomide—Dry mouth—Estradiol—osteoporosis	5.98e-05	0.000304	CcSEcCtD
Thalidomide—Asthenia—Pamidronate—osteoporosis	5.97e-05	0.000304	CcSEcCtD
Thalidomide—Dizziness—Ethinyl Estradiol—osteoporosis	5.94e-05	0.000302	CcSEcCtD
Thalidomide—Confusional state—Estradiol—osteoporosis	5.91e-05	0.000301	CcSEcCtD
Thalidomide—Pruritus—Pamidronate—osteoporosis	5.89e-05	0.0003	CcSEcCtD
Thalidomide—Oedema—Estradiol—osteoporosis	5.86e-05	0.000298	CcSEcCtD
Thalidomide—Infection—Estradiol—osteoporosis	5.82e-05	0.000296	CcSEcCtD
Thalidomide—Urticaria—Conjugated Estrogens—osteoporosis	5.82e-05	0.000296	CcSEcCtD
Thalidomide—Dizziness—Risedronate—osteoporosis	5.79e-05	0.000295	CcSEcCtD
Thalidomide—Body temperature increased—Conjugated Estrogens—osteoporosis	5.79e-05	0.000295	CcSEcCtD
Thalidomide—Abdominal pain—Conjugated Estrogens—osteoporosis	5.79e-05	0.000295	CcSEcCtD
Thalidomide—Shock—Estradiol—osteoporosis	5.76e-05	0.000294	CcSEcCtD
Thalidomide—Nervous system disorder—Estradiol—osteoporosis	5.75e-05	0.000293	CcSEcCtD
Thalidomide—Tachycardia—Estradiol—osteoporosis	5.72e-05	0.000291	CcSEcCtD
Thalidomide—Vomiting—Ethinyl Estradiol—osteoporosis	5.71e-05	0.000291	CcSEcCtD
Thalidomide—Diarrhoea—Pamidronate—osteoporosis	5.7e-05	0.00029	CcSEcCtD
Thalidomide—Skin disorder—Estradiol—osteoporosis	5.69e-05	0.00029	CcSEcCtD
Thalidomide—Hyperhidrosis—Estradiol—osteoporosis	5.66e-05	0.000288	CcSEcCtD
Thalidomide—Rash—Ethinyl Estradiol—osteoporosis	5.66e-05	0.000288	CcSEcCtD
Thalidomide—Dermatitis—Ethinyl Estradiol—osteoporosis	5.66e-05	0.000288	CcSEcCtD
Thalidomide—Headache—Ethinyl Estradiol—osteoporosis	5.63e-05	0.000287	CcSEcCtD
Thalidomide—Hypersensitivity—Zoledronate—osteoporosis	5.6e-05	0.000285	CcSEcCtD
Thalidomide—Vomiting—Risedronate—osteoporosis	5.57e-05	0.000284	CcSEcCtD
Thalidomide—Rash—Risedronate—osteoporosis	5.52e-05	0.000281	CcSEcCtD
Thalidomide—Dermatitis—Risedronate—osteoporosis	5.52e-05	0.000281	CcSEcCtD
Thalidomide—Dizziness—Pamidronate—osteoporosis	5.5e-05	0.00028	CcSEcCtD
Thalidomide—Headache—Risedronate—osteoporosis	5.49e-05	0.000279	CcSEcCtD
Thalidomide—Asthenia—Zoledronate—osteoporosis	5.46e-05	0.000278	CcSEcCtD
Thalidomide—Hypersensitivity—Conjugated Estrogens—osteoporosis	5.39e-05	0.000275	CcSEcCtD
Thalidomide—Pruritus—Zoledronate—osteoporosis	5.38e-05	0.000274	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Estradiol—osteoporosis	5.34e-05	0.000272	CcSEcCtD
Thalidomide—Nausea—Ethinyl Estradiol—osteoporosis	5.33e-05	0.000272	CcSEcCtD
Thalidomide—Insomnia—Estradiol—osteoporosis	5.3e-05	0.00027	CcSEcCtD
Thalidomide—Vomiting—Pamidronate—osteoporosis	5.29e-05	0.00027	CcSEcCtD
Thalidomide—Paraesthesia—Estradiol—osteoporosis	5.26e-05	0.000268	CcSEcCtD
Thalidomide—Asthenia—Conjugated Estrogens—osteoporosis	5.25e-05	0.000268	CcSEcCtD
Thalidomide—Rash—Pamidronate—osteoporosis	5.25e-05	0.000267	CcSEcCtD
Thalidomide—Dermatitis—Pamidronate—osteoporosis	5.24e-05	0.000267	CcSEcCtD
Thalidomide—Dyspnoea—Estradiol—osteoporosis	5.22e-05	0.000266	CcSEcCtD
Thalidomide—Headache—Pamidronate—osteoporosis	5.21e-05	0.000266	CcSEcCtD
Thalidomide—Somnolence—Estradiol—osteoporosis	5.21e-05	0.000265	CcSEcCtD
Thalidomide—Diarrhoea—Zoledronate—osteoporosis	5.2e-05	0.000265	CcSEcCtD
Thalidomide—Nausea—Risedronate—osteoporosis	5.2e-05	0.000265	CcSEcCtD
Thalidomide—Pruritus—Conjugated Estrogens—osteoporosis	5.18e-05	0.000264	CcSEcCtD
Thalidomide—Dyspepsia—Estradiol—osteoporosis	5.16e-05	0.000263	CcSEcCtD
Thalidomide—Decreased appetite—Estradiol—osteoporosis	5.09e-05	0.000259	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Estradiol—osteoporosis	5.06e-05	0.000258	CcSEcCtD
Thalidomide—Fatigue—Estradiol—osteoporosis	5.05e-05	0.000257	CcSEcCtD
Thalidomide—Dizziness—Zoledronate—osteoporosis	5.03e-05	0.000256	CcSEcCtD
Thalidomide—Pain—Estradiol—osteoporosis	5.01e-05	0.000255	CcSEcCtD
Thalidomide—Constipation—Estradiol—osteoporosis	5.01e-05	0.000255	CcSEcCtD
Thalidomide—Diarrhoea—Conjugated Estrogens—osteoporosis	5.01e-05	0.000255	CcSEcCtD
Thalidomide—Nausea—Pamidronate—osteoporosis	4.94e-05	0.000252	CcSEcCtD
Thalidomide—Dizziness—Conjugated Estrogens—osteoporosis	4.84e-05	0.000247	CcSEcCtD
Thalidomide—Vomiting—Zoledronate—osteoporosis	4.83e-05	0.000246	CcSEcCtD
Thalidomide—Feeling abnormal—Estradiol—osteoporosis	4.83e-05	0.000246	CcSEcCtD
Thalidomide—Rash—Zoledronate—osteoporosis	4.79e-05	0.000244	CcSEcCtD
Thalidomide—Gastrointestinal pain—Estradiol—osteoporosis	4.79e-05	0.000244	CcSEcCtD
Thalidomide—Dermatitis—Zoledronate—osteoporosis	4.79e-05	0.000244	CcSEcCtD
Thalidomide—Headache—Zoledronate—osteoporosis	4.76e-05	0.000243	CcSEcCtD
Thalidomide—Vomiting—Conjugated Estrogens—osteoporosis	4.65e-05	0.000237	CcSEcCtD
Thalidomide—Urticaria—Estradiol—osteoporosis	4.65e-05	0.000237	CcSEcCtD
Thalidomide—Body temperature increased—Estradiol—osteoporosis	4.63e-05	0.000236	CcSEcCtD
Thalidomide—Abdominal pain—Estradiol—osteoporosis	4.63e-05	0.000236	CcSEcCtD
Thalidomide—Rash—Conjugated Estrogens—osteoporosis	4.62e-05	0.000235	CcSEcCtD
Thalidomide—Dermatitis—Conjugated Estrogens—osteoporosis	4.61e-05	0.000235	CcSEcCtD
Thalidomide—Headache—Conjugated Estrogens—osteoporosis	4.59e-05	0.000234	CcSEcCtD
Thalidomide—Nausea—Zoledronate—osteoporosis	4.52e-05	0.00023	CcSEcCtD
Thalidomide—Nausea—Conjugated Estrogens—osteoporosis	4.35e-05	0.000221	CcSEcCtD
Thalidomide—Hypersensitivity—Estradiol—osteoporosis	4.32e-05	0.00022	CcSEcCtD
Thalidomide—Asthenia—Estradiol—osteoporosis	4.2e-05	0.000214	CcSEcCtD
Thalidomide—Pruritus—Estradiol—osteoporosis	4.15e-05	0.000211	CcSEcCtD
Thalidomide—Diarrhoea—Estradiol—osteoporosis	4.01e-05	0.000204	CcSEcCtD
Thalidomide—Dizziness—Estradiol—osteoporosis	3.87e-05	0.000197	CcSEcCtD
Thalidomide—Vomiting—Estradiol—osteoporosis	3.73e-05	0.00019	CcSEcCtD
Thalidomide—Rash—Estradiol—osteoporosis	3.69e-05	0.000188	CcSEcCtD
Thalidomide—Dermatitis—Estradiol—osteoporosis	3.69e-05	0.000188	CcSEcCtD
Thalidomide—Headache—Estradiol—osteoporosis	3.67e-05	0.000187	CcSEcCtD
Thalidomide—Nausea—Estradiol—osteoporosis	3.48e-05	0.000177	CcSEcCtD
Thalidomide—PTGS2—Disease—ACP5—osteoporosis	1.89e-05	0.000178	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTHLH—osteoporosis	1.87e-05	0.000176	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BMP2—osteoporosis	1.87e-05	0.000176	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PKM—osteoporosis	1.87e-05	0.000176	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—FDPS—osteoporosis	1.87e-05	0.000176	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—osteoporosis	1.87e-05	0.000176	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PSMA2—osteoporosis	1.87e-05	0.000176	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PSMA5—osteoporosis	1.87e-05	0.000176	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—OXCT1—osteoporosis	1.85e-05	0.000174	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TPI1—osteoporosis	1.85e-05	0.000174	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CA2—osteoporosis	1.85e-05	0.000174	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—osteoporosis	1.84e-05	0.000173	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGB—osteoporosis	1.83e-05	0.000173	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AGER—osteoporosis	1.82e-05	0.000171	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ADCY5—osteoporosis	1.81e-05	0.000171	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MGLL—osteoporosis	1.8e-05	0.00017	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ATIC—osteoporosis	1.78e-05	0.000168	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PNP—osteoporosis	1.78e-05	0.000168	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPD2—osteoporosis	1.77e-05	0.000167	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PGLS—osteoporosis	1.77e-05	0.000167	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PSMA2—osteoporosis	1.77e-05	0.000167	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PSMA5—osteoporosis	1.77e-05	0.000167	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—osteoporosis	1.76e-05	0.000166	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	1.75e-05	0.000165	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TPI1—osteoporosis	1.75e-05	0.000165	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—osteoporosis	1.75e-05	0.000164	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—P4HB—osteoporosis	1.74e-05	0.000164	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CALCA—osteoporosis	1.74e-05	0.000164	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—IDH2—osteoporosis	1.73e-05	0.000163	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GAPDH—osteoporosis	1.71e-05	0.000161	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.7e-05	0.00016	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—POMC—osteoporosis	1.7e-05	0.00016	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ADCY5—osteoporosis	1.68e-05	0.000158	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IRS2—osteoporosis	1.67e-05	0.000158	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—RAP1A—osteoporosis	1.66e-05	0.000157	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CALCA—osteoporosis	1.65e-05	0.000155	CbGpPWpGaD
Thalidomide—PTGS2—Disease—P4HB—osteoporosis	1.65e-05	0.000155	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—IDH2—osteoporosis	1.63e-05	0.000153	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP27A1—osteoporosis	1.62e-05	0.000153	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PNP—osteoporosis	1.62e-05	0.000153	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ATIC—osteoporosis	1.62e-05	0.000153	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—IDH2—osteoporosis	1.62e-05	0.000153	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GAPDH—osteoporosis	1.62e-05	0.000152	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—FDPS—osteoporosis	1.6e-05	0.000151	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PKM—osteoporosis	1.6e-05	0.000151	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.59e-05	0.00015	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.59e-05	0.00015	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IRS2—osteoporosis	1.59e-05	0.00015	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ACP5—osteoporosis	1.58e-05	0.000149	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KL—osteoporosis	1.58e-05	0.000149	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TGFB1—osteoporosis	1.58e-05	0.000149	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.56e-05	0.000147	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MTHFR—osteoporosis	1.54e-05	0.000145	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NFATC1—osteoporosis	1.54e-05	0.000145	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—IDH2—osteoporosis	1.53e-05	0.000144	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP27A1—osteoporosis	1.53e-05	0.000144	CbGpPWpGaD
Thalidomide—PTGS2—Disease—DKK1—osteoporosis	1.53e-05	0.000144	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP27A1—osteoporosis	1.53e-05	0.000144	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPD2—osteoporosis	1.52e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PGLS—osteoporosis	1.52e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—OXCT1—osteoporosis	1.51e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CA2—osteoporosis	1.51e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KL—osteoporosis	1.5e-05	0.000141	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ACP5—osteoporosis	1.49e-05	0.00014	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.48e-05	0.00014	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ACP5—osteoporosis	1.48e-05	0.00014	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MGLL—osteoporosis	1.48e-05	0.000139	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—osteoporosis	1.47e-05	0.000139	CbGpPWpGaD
Thalidomide—PTGS2—Disease—WNT1—osteoporosis	1.47e-05	0.000138	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TPI1—osteoporosis	1.47e-05	0.000138	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IRS2—osteoporosis	1.47e-05	0.000138	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IRS1—osteoporosis	1.46e-05	0.000138	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.45e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP27A1—osteoporosis	1.44e-05	0.000136	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGA—osteoporosis	1.43e-05	0.000135	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ACP5—osteoporosis	1.4e-05	0.000132	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.39e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PNP—osteoporosis	1.39e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ATIC—osteoporosis	1.39e-05	0.000131	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IRS1—osteoporosis	1.39e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.38e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TPI1—osteoporosis	1.38e-05	0.00013	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—P4HB—osteoporosis	1.38e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CA2—osteoporosis	1.38e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—OXCT1—osteoporosis	1.38e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TPI1—osteoporosis	1.38e-05	0.00013	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6R—osteoporosis	1.37e-05	0.000129	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GAPDH—osteoporosis	1.36e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MGLL—osteoporosis	1.34e-05	0.000127	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ENO1—osteoporosis	1.34e-05	0.000127	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PSMA2—osteoporosis	1.32e-05	0.000125	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PSMA5—osteoporosis	1.32e-05	0.000125	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—RAP1A—osteoporosis	1.32e-05	0.000124	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TPI1—osteoporosis	1.3e-05	0.000123	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6R—osteoporosis	1.3e-05	0.000123	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—P4HB—osteoporosis	1.3e-05	0.000122	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—P4HB—osteoporosis	1.3e-05	0.000122	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IRS1—osteoporosis	1.28e-05	0.000121	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GAPDH—osteoporosis	1.28e-05	0.00012	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ENO1—osteoporosis	1.27e-05	0.00012	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GAPDH—osteoporosis	1.27e-05	0.00012	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.27e-05	0.000119	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PSMA5—osteoporosis	1.26e-05	0.000118	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PSMA2—osteoporosis	1.26e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—IDH2—osteoporosis	1.25e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—RAP1A—osteoporosis	1.24e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—RAP1A—osteoporosis	1.24e-05	0.000117	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ADCY5—osteoporosis	1.24e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—P4HB—osteoporosis	1.23e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GAPDH—osteoporosis	1.2e-05	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6R—osteoporosis	1.2e-05	0.000113	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—osteoporosis	1.2e-05	0.000113	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SPP1—osteoporosis	1.2e-05	0.000113	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—osteoporosis	1.19e-05	0.000112	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CA2—osteoporosis	1.18e-05	0.000111	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—OXCT1—osteoporosis	1.18e-05	0.000111	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP27A1—osteoporosis	1.18e-05	0.000111	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ADCY5—osteoporosis	1.17e-05	0.00011	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—RAP1A—osteoporosis	1.17e-05	0.00011	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CALCA—osteoporosis	1.17e-05	0.00011	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.15e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MGLL—osteoporosis	1.15e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ACP5—osteoporosis	1.15e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—IDH2—osteoporosis	1.14e-05	0.000108	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SPP1—osteoporosis	1.14e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.13e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.08e-05	0.000102	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IRS2—osteoporosis	1.08e-05	0.000102	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP27A1—osteoporosis	1.08e-05	0.000101	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP19A1—osteoporosis	1.07e-05	0.000101	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ENO1—osteoporosis	1.07e-05	0.0001	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPI1—osteoporosis	1.07e-05	0.0001	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KL—osteoporosis	1.06e-05	0.0001	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LEP—osteoporosis	1.06e-05	9.97e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PSMA5—osteoporosis	1.05e-05	9.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PSMA2—osteoporosis	1.05e-05	9.9e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—osteoporosis	1.05e-05	9.88e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ACP5—osteoporosis	1.05e-05	9.85e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—osteoporosis	1.04e-05	9.83e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.03e-05	9.72e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IRS2—osteoporosis	1.03e-05	9.67e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.02e-05	9.62e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ESR1—osteoporosis	1.01e-05	9.52e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LEP—osteoporosis	1e-05	9.46e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ENO1—osteoporosis	1e-05	9.46e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—P4HB—osteoporosis	1e-05	9.44e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ENO1—osteoporosis	1e-05	9.44e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—osteoporosis	9.96e-06	9.38e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—osteoporosis	9.91e-06	9.33e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PSMA5—osteoporosis	9.9e-06	9.32e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PSMA2—osteoporosis	9.9e-06	9.32e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PSMA2—osteoporosis	9.88e-06	9.3e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PSMA5—osteoporosis	9.88e-06	9.3e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GAPDH—osteoporosis	9.84e-06	9.27e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—IDH2—osteoporosis	9.77e-06	9.2e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPI1—osteoporosis	9.72e-06	9.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ESR1—osteoporosis	9.59e-06	9.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—RAP1A—osteoporosis	9.59e-06	9.03e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ENO1—osteoporosis	9.47e-06	8.92e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IRS1—osteoporosis	9.45e-06	8.89e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PSMA2—osteoporosis	9.33e-06	8.79e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PSMA5—osteoporosis	9.33e-06	8.79e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP27A1—osteoporosis	9.19e-06	8.65e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—P4HB—osteoporosis	9.14e-06	8.61e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—osteoporosis	9.1e-06	8.56e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—osteoporosis	9.05e-06	8.53e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GAPDH—osteoporosis	8.97e-06	8.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IRS1—osteoporosis	8.96e-06	8.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ACP5—osteoporosis	8.94e-06	8.42e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6R—osteoporosis	8.87e-06	8.35e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	8.82e-06	8.31e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ADCY5—osteoporosis	8.78e-06	8.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1—osteoporosis	8.75e-06	8.24e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GPX1—osteoporosis	8.75e-06	8.24e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—RAP1A—osteoporosis	8.74e-06	8.23e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—osteoporosis	8.63e-06	8.13e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP19A1—osteoporosis	8.53e-06	8.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6R—osteoporosis	8.42e-06	7.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	8.36e-06	7.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ADCY5—osteoporosis	8.32e-06	7.83e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPI1—osteoporosis	8.31e-06	7.82e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1—osteoporosis	8.3e-06	7.82e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—osteoporosis	8.07e-06	7.6e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP19A1—osteoporosis	8.03e-06	7.56e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP19A1—osteoporosis	8.01e-06	7.54e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—P4HB—osteoporosis	7.81e-06	7.36e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO1—osteoporosis	7.75e-06	7.3e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GAPDH—osteoporosis	7.67e-06	7.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—osteoporosis	7.65e-06	7.21e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PSMA2—osteoporosis	7.64e-06	7.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PSMA5—osteoporosis	7.64e-06	7.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	7.62e-06	7.18e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP19A1—osteoporosis	7.57e-06	7.13e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RAP1A—osteoporosis	7.47e-06	7.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IRS2—osteoporosis	7.28e-06	6.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—osteoporosis	7.12e-06	6.71e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—osteoporosis	7.11e-06	6.69e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ENO1—osteoporosis	7.07e-06	6.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADCY5—osteoporosis	6.97e-06	6.56e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSMA2—osteoporosis	6.96e-06	6.56e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSMA5—osteoporosis	6.96e-06	6.56e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPX1—osteoporosis	6.94e-06	6.54e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADCY5—osteoporosis	6.56e-06	6.18e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADCY5—osteoporosis	6.55e-06	6.16e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPX1—osteoporosis	6.54e-06	6.16e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPX1—osteoporosis	6.52e-06	6.14e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.51e-06	6.13e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—osteoporosis	6.46e-06	6.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—osteoporosis	6.41e-06	6.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IRS1—osteoporosis	6.36e-06	5.98e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP19A1—osteoporosis	6.19e-06	5.83e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADCY5—osteoporosis	6.18e-06	5.82e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—osteoporosis	6.16e-06	5.8e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—osteoporosis	6.11e-06	5.76e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO1—osteoporosis	6.04e-06	5.68e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—osteoporosis	6.03e-06	5.68e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—osteoporosis	6.02e-06	5.67e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6R—osteoporosis	5.97e-06	5.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSMA2—osteoporosis	5.95e-06	5.6e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSMA5—osteoporosis	5.95e-06	5.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—osteoporosis	5.8e-06	5.46e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—osteoporosis	5.69e-06	5.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP19A1—osteoporosis	5.65e-06	5.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—osteoporosis	5.36e-06	5.04e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—osteoporosis	5.26e-06	4.95e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—osteoporosis	5.25e-06	4.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—osteoporosis	5.13e-06	4.83e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADCY5—osteoporosis	5.06e-06	4.77e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—osteoporosis	5.04e-06	4.75e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—osteoporosis	4.99e-06	4.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—osteoporosis	4.98e-06	4.69e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP19A1—osteoporosis	4.83e-06	4.54e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—osteoporosis	4.83e-06	4.54e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—osteoporosis	4.82e-06	4.53e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—osteoporosis	4.65e-06	4.38e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADCY5—osteoporosis	4.61e-06	4.35e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—osteoporosis	4.6e-06	4.33e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—osteoporosis	4.55e-06	4.28e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—osteoporosis	4.24e-06	4e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—osteoporosis	3.95e-06	3.72e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADCY5—osteoporosis	3.94e-06	3.71e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—osteoporosis	3.93e-06	3.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—osteoporosis	3.75e-06	3.53e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—osteoporosis	3.72e-06	3.51e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—osteoporosis	3.63e-06	3.42e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—osteoporosis	3.54e-06	3.33e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—osteoporosis	3.53e-06	3.32e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—osteoporosis	3.39e-06	3.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—osteoporosis	2.9e-06	2.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—osteoporosis	2.66e-06	2.5e-05	CbGpPWpGaD
